Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Featured Stories

Abuse-Deterrent Opioids: Where Are They Now?

The potential blockbuster category for abuse-deterrent opioids has fizzled. A few stalwarts are pushing on, but the return on investment for many drug manufacturers has been disappointing. Scrip tracked how opioids approved in the last eight years have performed.

Market Access Pricing Strategies Neurology

Roche Gains With Tecentriq IMpower131 NSCLC Data, But For How Long?

Roche is "first to market" with Phase III Tecentriq data in first-line squamous NSCLC setting, but analysts note Merck and Bristol are not far behind.

Analysis Clinical Trials Commercial

Seattle Genetics Says Adcetris Sets New Standard In Frontline Lymphoma

The market for a new FDA-approved indication in frontline classical Hodgkin lymphoma could be worth $650m to $750m, some analysts say.

Approvals Cancer Clinical Trials

 Recent Tweets from Scrip


Commercial Explore this Topic

Set Alert for Commercial

Orsenix Eyes Opportunity For Oral Arsenic Leukemia Therapy

Teva's Trisenox, an IV formulation of arsenic trioxide, was recently approved by the FDA as a first-line treatment for acute promyelocytic leukemia but Incyte founder Kris Vaddi's Orsenix believes its Phase III-ready oral version will take over the market.

Cancer Clinical Trials FDA

Arena Ready For Etrasimod Phase III Face-Off With Celgene's Ozanimod In UC

With significant Phase II results in ulcerative colitis, Arena is planning a Phase III program for its selective S1P receptor modulator etrasimod – a drug that it thinks can best Celgene's S1P-targeting therapy ozanimod on safety and possibly efficacy.

Gastrointestinal Immune Disorders Clinical Trials

Ilumya Becomes Sun's New Branded Specialty Drug Pillar

FDA approved Ilumya for moderate to severe plaque psoriasis, furthering the competitive dynamics in the crowded psoriasis market, and establishing the biologic as a major pillar of Sun's new branded specialty drug business.

Approvals Dermatology

Turkey's Abdi Ibrahim Beats Multinationals On Domestic Pharma Market

The Turkish pharmaceutical market reached $5.6bn in 2017. Despite strong competition from multinationals, Abdi Ibrahim, a local company, was market leader last year with a turnover of $380m. It was followed by Novartis and Pfizer.

Turkey Market Intelligence

TCR2 Raises $125m To Make T-Cell Therapies Available To More Cancer Patients

TCR2 Therapeutics raised a $125m Series B round to take two T-cell receptor (TCR)-based therapies into the clinic for solid tumors. The company's technology platform overcomes HLA-matching issues to make TCR-based treatments available to more patients.

Financing ImmunoOncology

Zealand Rushes Out Good Safety News On Phase III Dasiglucagon Rescue Pen

Early results confirm dasiglucagon's safety profile with no treatment-induced or treatment-boosted anti-drug antibodies.

Clinical Trials Commercial

TPP Matches Chinese Pharma & Capital With Western Assets

Finding the right partner to enter the Chinese pharma market or access Chinese capital is not a trivial exercise for Western companies. Speaking at the 2018 Biotech Showcase, Tony Chu, founder and managing partner of TPP Healthcare, told Scrip that the advisory company was established to help Western companies achieve their Chinese goals. The sweet spot is late-stage assets for joint venturing or cash thirsty biotechs with programs focused on Asia Pacific health challenges.

Asia Pacific Deals

Merger Buzz Boosts Shares Of India's Troubled Fortis

Shares of Indian hospital chain Fortis Healthcare have risen some 16% in the past month, fuelled by investor hopes of a takeover battle for the financially troubled company. US hedge fund Elliott Management is now said to have entered the fray and be buying up stock.

India Commercial

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

MIFID II May Hit Small & Midcap EU Biotech Investment

New EU regulation designed to offer greater protection and more transparency for investors could have serious implications for Europe’s small to midcap biotechs just as the European Investment Bank predicts a potential €40bn funding shortfall in key bioclusters by 2021.


Europe Commercial Financing

Drug Pricing: A Game Of Chutes & Ladders

The US drug pricing policy environment is facing changes. Much of the action, whether Congressional or regulatory, is good for industry – but there have been a few setbacks and more may come.

Market Access Pricing Debate

The Ups and Downs Of US Drug Pricing Policy

If 2017 was the year of talk (tweets) on prescription drug pricing policy, 2018 is shaping up to be the year of action.

Pricing Debate Market Access

Exelixis Eyes Liver Cancer OK To Help Drive Cabometyx Sales

Exelixis is looking to get its kidney cancer drug Cabometyx approved for hepatocellular carcinoma as well, but the therapy's long-term success is reliant on combinations with checkpoint inhibitors

Cancer Drug Review

Research & Development Explore this Topic

Set Alert for Research & Development

Ocugen Heads Toward Phase III In Dry Eye With Potential Benefits Over Older Drugs

Biotech hopes to counter established Restasis and Xiidra in dry eye with a combination of two approved ophthalmology eye drops, offering quicker onset of action, tolerability and strong efficacy.
Clinical Trials Business Strategies Research & Development

Celgene Further Commits To Neuroscience With Prothena Pact

It is a risky business but the biotech major is paying $150m upfront, and potentially hundreds of millions of dollars more, to work with Prothena and develop therapies targeted at proteins implicated in highly challenging neurodegenerative diseases such as Alzheimer's and ALS.

Neurology Deals

PANORAMA Helps Regeneron's Eylea Even Score With Roche's Lucentis

Phase III PANORAMA looks good, so far, for Regeneron's Eylea in diabetic retinopathy without edema.

Ophthalmic Clinical Trials

Cidara To Take Rezafungin Into Phase III In Two Severe Infection Indications

Two-week treatment data comparing the investigational echinocandin antifungal with caspofungin shows trend toward better cure rate with similar efficacy. Cidara plans Phase III trials for treatment and prevention of difficult-to-treat infections.
Research & Development Infectious Diseases